Garvey Katharine, Wolfsdorf Joseph I
Division of Endocrinology, Department of Medicine, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA.
Division of Endocrinology, Department of Medicine, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA.
Pediatr Clin North Am. 2015 Aug;62(4):873-88. doi: 10.1016/j.pcl.2015.04.005. Epub 2015 May 16.
Technological innovations have revolutionized the treatment of type 1 diabetes. Although technological advances can potentially improve diabetes outcomes, maintenance of target glycemic control, at the present time, remains largely dependent on patient and family motivation, competence, and adherence to daily diabetes care requirements. Trials of closed loop or "artificial pancreas" technology show great promise to automate insulin delivery and achieve near normal glucose control and reduced hypoglycemia with minimal patient intervention.
技术创新彻底改变了1型糖尿病的治疗方式。尽管技术进步有可能改善糖尿病治疗效果，但目前，维持目标血糖控制在很大程度上仍依赖于患者及其家人的积极性、能力以及对日常糖尿病护理要求的依从性。闭环或“人工胰腺”技术试验显示出巨大的前景，能够实现胰岛素输送自动化，以最少的患者干预实现接近正常的血糖控制并减少低血糖情况。
